Barrett's esophagus
Conditions
Interventions
Phase I:
Endoscopic resection with Captivator EMR device and with Duette EMR device (currently used EMR device) of esophageal tissue prior to esophagectomy
Phase II:
Endoscopic resection of Barrett
Sponsors
Academic Medial center Amsterdam, the Netherlands
Eligibility
Inclusion criteria
Inclusion criteria: Phase I 1.Age 18-80 years 2.Subject is scheduled for esophagectomy 3.Subject is willing to participate, fully understands the content of the informed consent form, and signs the informed consent form. Phase II 1.Age 18-80 years 2.Barrett’s esophagus with a visible abnormality and biopsy-proven high grade dysplasia and/or early cancer 3.Lesion with a maximum size of 4 cm in longitudinal length and 50% of the circumference. 4.No suspicion of submucosal invasion, based on the macroscopic appearance and/or endosonography 5.No signs of lymph node and/or distant metastasis on endosonography and CT-scanning of the thorax and abdomen. 6.Patient is scheduled for endoscopic resection of present BE neoplasia 7.Subject is willing to participate, fully understands the content of the informed consent form, and signs the informed consent form.
Exclusion criteria
Exclusion criteria: Phase I 1.Subject has previously undergone endoscopic therapy in the intended treatment zone, including (but not limited to) cryospray therapy, laser treatment, photodynamic therapy, endoscopic mucosal resection, radiofrequency ablation or argon plasma coagulation. 2.Presence of esophageal stenosis limiting access to the intended treatment zone. 3.Scarring by other causes of the intended treatment zone. 4.Subject refuses or is not able to provide written informed consent. Phase II 1.Subject has previously undergone endoscopic therapy in the intended treatment zone, including (but not limited to) cryospray therapy, laser treatment, photodynamic therapy, endoscopic mucosal resection, radiofrequency ablation or argon plasma coagulation. 2.Presence of esophageal stenosis limiting access to the intended treatment zone. 3.Scarring by any cause of the intended treatment zone. 4.Subject refuses or is not able to provide written informed consent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Phase I 1)Maximum diameter of the resection specimens retrieved with the CaptivatorTM -and DuetteTM devices. Phase II 1)Percentage of successful endoscopic resection (i.e. resection of all lesion delineation markings) | — |
Secondary
| Measure | Time frame |
|---|---|
| Phase I 1)Difference in the number of device or procedure related complications, such as bleeding or perforation, experienced with the CaptivatorTM device compared to the DuetteTM device. 2)Visibility of the CaptivatorTM device and the DuetteTM device (pre- and post-procedure). 3)Ease of endoscopic resection 4)Procedure time Phase II 1)Number and severity of any acute (during procedure) or early (0-48 hours) device or procedure related complications such as bleeding or perforation during endoscopic resection with the CaptivatorTM device. Complications are registered only if they are clinically significant. 2)Presence of any late complications (> 48 hours) such as bleeding or perforation during endoscopic resection with the CaptivatorTM device. Complications are registered only if they are clinically significant. 3)Procedure time | — |
Contacts
Public ContactKamar Belghazi
Meibergdreef 9 - room B1-245
Outcome results
None listed